{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:25:43Z","timestamp":1789475143606,"version":"build-2803163510"},"reference-count":33,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Cephalalgia"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate whether the conventional \u226550% reduction in monthly migraine days (MMDs) accurately reflects clinically meaningful benefit compared with IHS-aspired migraine control definitions in difficult-to-treat high-frequency episodic migraine (HFEM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this post-hoc analysis of a prospective, real-world registry, conducted by the Greek Research Alliance for the Study of Headache and Pain (GRASP), 114 HFEM patients who had failed \u22653 preventive therapies and achieved a sustained \u226550% reduction in MMDs with monthly fremanezumab over 24 months, were included. Treatment response (\u226550% and \u226575% MMD reduction) and IHS-defined control states (freedom, optimal, modest, insufficient control) were assessed using headache diaries at baseline (T0), month 12 (T1), and month 24 (T2). Secondary outcomes included headache intensity, analgesic use, and migraine-related disability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At T1, fremanezumab significantly improved all efficacy and disability outcomes (p\u2009&lt;\u20090.001), with mean MMDs reduced from 11.9 at baseline to 5.1 at T1. While 78.1% achieved \u226550% MMD reduction, only 19.3% reached optimal control (&lt;4 MMDs), highlighting a mismatch between relative response and true disease control. At T2, MMDs further declined to 4.3, while optimal control increased to 29.8% and insufficient control declined to 7.8%. Overall, most patients remained moderately controlled (60.6%) with residual 4\u20136 MMDs. Non-prior exposure to other anti-CGRP therapies emerged as the only independent predictor of optimal long-term control (OR:2.1; p\u2009=\u20090.03).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Achieving a\u2009\u2265\u200950% MMD reduction with CGRP-targeted therapies may not always correspond to clinically-meaningful benefit. More ambitious outcome measures are essential for more accurately evaluating treatment effectiveness and achieving clinically-meaningful reduction of migraine's disability.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/03331024261456247","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T08:23:16Z","timestamp":1780561396000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Achieving International Headache Society-aspired optimal migraine control in fremanezumab-treated patients: A post-hoc analysis of a real-world, prospective study from the GRASP study group"],"prefix":"10.1177","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2131-7114","authenticated-orcid":false,"given":"Andreas A.","family":"Argyriou","sequence":"first","affiliation":[{"name":"Headache Outpatient Clinic, Neurology Department, Agios Andreas General Hospital of Patras, Patras, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9275-0076","authenticated-orcid":false,"given":"Emmanouil V.","family":"Dermitzakis","sequence":"additional","affiliation":[{"name":"General Clinic, Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Rikos","sequence":"additional","affiliation":[{"name":"Department of Neurology, .404 Military Hospital, Larisa, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Chondrogianni","sequence":"additional","affiliation":[{"name":"National and Kapodistrian University of Athens"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aikaterini","family":"Foska","sequence":"additional","affiliation":[{"name":"National and Kapodistrian University of Athens"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Soldatos","sequence":"additional","affiliation":[{"name":"Kalamata Headache Clinic, Kalamata, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Mavraki","sequence":"additional","affiliation":[{"name":"Neurology Department, Democritus University of Thrace, Alexandroupolis, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia","family":"Xiromerisiou","sequence":"additional","affiliation":[{"name":"Institute of Preventive Neurology and Brain Health-Mindful Mind"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pantelis","family":"Litsardopoulos","sequence":"additional","affiliation":[{"name":"Headache Outpatient Clinic, Neurology Department, Agios Andreas General Hospital of Patras, Patras, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Tsivgoulis","sequence":"additional","affiliation":[{"name":"National and Kapodistrian University of Athens"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2715-7898","authenticated-orcid":false,"given":"Michail","family":"Vikelis","sequence":"additional","affiliation":[{"name":"Glyfada Headache Clinic"},{"name":"Greek Society of Migraine and Headache Patients, Athens, Greece"},{"name":"Mediterraneo Hospital Headache Clinic, Glyfada, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the Greek Research Alliance for the Study of Headache and Pain (GRASP) Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32162-0"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1177\/0333102411398400"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/head.13421"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/head.13688"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-023-00438-z"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1177\/03331024241305381"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-023-01671-5"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-021-01335-2"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)00109-6"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-024-00583-9"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-025-12911-w"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-025-08484-1"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15740"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12134526"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13020386"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1177\/03331024251320608"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/ene.70327"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417738202"},{"key":"e_1_3_2_20_2","unstructured":"Teva Pharmaceuticals USA Inc. Highlights for Prescribing Information. AJOVY TM (fremanezumab-vfrm) injection for subcutaneous use. Initial U.S. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761089s000lbl.pdf (2018 assessed 1 March 2026)."},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1177\/03331024231166625"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.1999.019002107.x"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1026119331193"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s41669-017-0034-3"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-022-01408-w"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2024.2365312"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418758283"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1177\/0333102420941839"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000010600"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12192-9"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000214659"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-023-01394-0"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2025.2461766"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1177\/03331024251414659"}],"container-title":["Cephalalgia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03331024261456247","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/03331024261456247","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03331024261456247","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T08:16:43Z","timestamp":1780733803000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/03331024261456247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1177\/03331024261456247"],"URL":"https:\/\/doi.org\/10.1177\/03331024261456247","relation":{},"ISSN":["0333-1024","1468-2982"],"issn-type":[{"value":"0333-1024","type":"print"},{"value":"1468-2982","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"article-number":"03331024261456247"}}